Latest Safety News

dorsaVi has initiated its Ultra-Edge Modular Design program, transitioning from IP development to a manufacturable hardware platform targeting robotics, exoskeletons, and industrial AI with ultra-low power consumption.

Anteris Technologies has treated the first US patients in its global PARADIGM trial, marking a key milestone in testing its DurAVR transcatheter heart valve against established devices.

Kingsrose Mining has appointed Andrew Caruso as its new CEO, bringing over three decades of mining leadership experience to drive its Scandinavian projects and acquisition strategy. His remuneration package includes a base salary of CND$400,000 plus performance-linked incentives tied to share price milestones.

Acusensus Limited maintains its FY26 revenue and EBITDA guidance while advancing multiple enforcement programs across the US, UK, New Zealand, and Australia, underpinned by new product developments and international growth.

Channel Infrastructure NZ Limited has accelerated key project completions and expanded contract scope, prompting a raised EBITDA forecast for FY2026 amid an uncertain fuel demand outlook.

MC Mining has secured a US$90 million capital injection from Kinetic Development Group, which now holds a 51% controlling stake, accelerating the Makhado Project towards production. New board appointments signal a strategic shift as the company pivots from development to operational ramp-up.

Emyria Limited reported $1.2 million in revenue for the March quarter, driven by insurer-funded clinics and strong clinical outcomes in PTSD treatment. The company is advancing its national clinic rollout, including new sites in Victoria and New South Wales, while launching a global partnership program targeting international drug sponsors.

Admiralty Resources has commissioned the transmission line at its Mariposa Iron Ore Project, securing direct grid power and reducing reliance on costly fuel generators.

NeuRizer Ltd advanced its urea project with Reliance Industries payments and environmental submissions, despite ongoing ASX trading suspension and overdue financial reports.

GR Production Services secures a five-year $57 million operations and maintenance contract at the Sturt Plateau Compression Facility in the Northern Territory's Beetaloo Basin, with potential extension for three more years.

PYC Therapeutics presented Phase 1/2 data at ARVO 2026 showing encouraging safety and efficacy signals for its RNA therapies targeting rare genetic eye diseases Retinitis Pigmentosa type 11 and Autosomal Dominant Optic Atrophy.

Entropy Neurodynamics has unveiled a striking 75% response rate in a small Phase 2a trial of its oral psilocybin therapy for treatment-resistant irritable bowel syndrome, far surpassing existing treatments and validating its gut-brain axis approach.